These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20363564)

  • 21. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
    Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
    Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic importance of thymidylate gene polymorphism in colon cancer stage II.
    Dysager L; Jensen LH; Lindebjerg J; Jakobsen A
    Int J Colorectal Dis; 2008 Dec; 23(12):1267. PubMed ID: 18629514
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of molecular markers in predicting response to therapy in patients with colorectal cancer.
    Shankaran V; Wisinski KB; Mulcahy MF; Benson AB
    Mol Diagn Ther; 2008; 12(2):87-98. PubMed ID: 18422373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
    Spano JP; Milano G; Vignot S; Khayat D
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of genomic markers in colorectal cancer treatment.
    Allen WL; Johnston PG
    J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer.
    Al-Hajeili M; Shields AF; Hwang JJ; Wadlow RC; Marshall JL
    Oncology (Williston Park); 2017 Apr; 31(4):301-12. PubMed ID: 28412781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
    Lièvre A; Laurent-Puig P
    Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
    Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
    Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palliative treatment of unresectable metastatic colorectal cancer.
    Fornaro L; Masi G; Loupakis F; Vasile E; Falcone A
    Expert Opin Pharmacother; 2010 Jan; 11(1):63-77. PubMed ID: 20001430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Validation study of KRAS mutation in colorectal cancer].
    Kopper L; Tímár J
    Magy Onkol; 2009 Dec; 53(4):361-6. PubMed ID: 20071308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
    Press OA; Zhang W; Gordon MA; Yang D; Lurje G; Iqbal S; El-Khoueiry A; Lenz HJ
    Cancer Res; 2008 Apr; 68(8):3037-42. PubMed ID: 18413774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Colorectal cancers: prognostic and predictive factors of response to treatment].
    Sablin MP; Italiano A; Spano JP
    Bull Cancer; 2009 Apr; 96(4):417-23. PubMed ID: 19357016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies.
    Denlinger CS; Cohen SJ
    Curr Treat Options Oncol; 2007 Oct; 8(5):339-51. PubMed ID: 18193357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.